Posted by linkadge on September 10, 2006, at 8:10:48
In reply to Re: What's new?-I'll second that!, posted by Tom Twilight on September 10, 2006, at 4:43:02
Not a whole lot. From my understanding the majority of the drugs that were in the pipelines a few years back have been discontinued for various reasons.
Certain promising drugs like valdoxan and gepirone were discontinued for lack of demonstration of efficacy, which is dumb in my opinion since these drugs were promising. Theres got to be more to the story.
Theres no way IMO that buspar be on the market but gepirone not. Gepirone is much more potent and selective. WTF.
There was a NK-1 antagonist discontinued for lack of demonstration of efficacy.
There is URB-597 which is FAAH inhibitor. It increases endogenious levels of anandamide, an endogenious marajuanna like substance. Applications being depression and anxiety.
I doubt this one will make it to the market. Its just too promising.There was a 5-ht1b autoreceptor antagonist, which in my opinion would be a very effective an fast acting depression treament.
There are so many reasons that drugs get dropped. Its sad.
Its not necessarily that these drugs with new targets are any less effective IMO, but I think that the FDA feels more comfortable approving a varient of something thats alread on the market.
Another reuptake inhibitor, eh, sure why not.
To be honest, I don't think you're going to see anything novel or worthwile for another 10 years.
Linkadge
poster:linkadge
thread:684651
URL: http://www.dr-bob.org/babble/20060909/msgs/684668.html